These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 18589181

  • 1. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.
    Shen Y, Wang X, Xia W, Wang C, Cai M, Xie H, Zhou L, Zheng S.
    Transplant Proc; 2008 Jun; 40(5):1727-33. PubMed ID: 18589181
    [Abstract] [Full Text] [Related]

  • 2. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells.
    Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X, Zheng S.
    Cancer Lett; 2007 Sep 08; 254(2):288-97. PubMed ID: 17462818
    [Abstract] [Full Text] [Related]

  • 3. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
    Ubai T, Azuma H, Kotake Y, Inamoto T, Takahara K, Ito Y, Kiyama S, Sakamoto T, Horie S, Muto S, Takahara S, Otsuki Y, Katsuoka Y.
    Anticancer Res; 2007 Sep 08; 27(1A):75-88. PubMed ID: 17352219
    [Abstract] [Full Text] [Related]

  • 4. FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.
    Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor J.
    Transplant Proc; 2007 Dec 08; 39(10):2992-6. PubMed ID: 18089307
    [Abstract] [Full Text] [Related]

  • 5. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
    Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, Bruns CJ, Jauch KW, Heeschen C, Graeb C.
    J Cell Biochem; 2007 May 01; 101(1):259-70. PubMed ID: 17203465
    [Abstract] [Full Text] [Related]

  • 6. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
    Stracke S, Ramudo L, Keller F, Henne-Bruns D, Mayer JM.
    Transplant Proc; 2006 Apr 01; 38(3):766-70. PubMed ID: 16647466
    [Abstract] [Full Text] [Related]

  • 7. Effect of FTY720 on apoptosis of smooth muscle cells.
    Böhler T, Guillebaud J, Etienne L, Canivet C, Kamar N, Rostaing L, Thiers JC, Galvani S, Augé N, Salvayre R, Nègre-Salvayre A, Thomsen M.
    Transplant Proc; 2007 Oct 01; 39(8):2624-6. PubMed ID: 17954194
    [Abstract] [Full Text] [Related]

  • 8. [Study of the effects of immunosuppressive agents on human islet cells in vitro].
    Cai JQ, Tan JM, Dong WP, Wang YF, Wang JB.
    Zhonghua Yi Xue Za Zhi; 2005 Mar 16; 85(10):654-6. PubMed ID: 15932724
    [Abstract] [Full Text] [Related]

  • 9. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.
    Cancer Chemother Pharmacol; 2008 Jul 16; 62(2):305-13. PubMed ID: 17912526
    [Abstract] [Full Text] [Related]

  • 10. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines.
    Heuer M, Benkö T, Cicinnati VR, Kaiser GM, Sotiropoulos GC, Baba HA, Treckmann JW, Broelsch CE, Paul A.
    Transplant Proc; 2009 Jul 16; 41(1):359-65. PubMed ID: 19249557
    [Abstract] [Full Text] [Related]

  • 11. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.
    Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A, Katsuoka Y.
    Cancer Res; 2002 Mar 01; 62(5):1410-9. PubMed ID: 11888913
    [Abstract] [Full Text] [Related]

  • 12. FTY720 inhibits tumor growth and angiogenesis.
    Schmid G, Guba M, Papyan A, Ischenko I, Brückel M, Bruns CJ, Jauch KW, Graeb C.
    Transplant Proc; 2005 Mar 01; 37(1):110-1. PubMed ID: 15808563
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.
    Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G.
    J Surg Res; 2010 Apr 01; 159(2):705-13. PubMed ID: 19482307
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of all-trans-retinoic acid on cultured human pancreatic cancer cells.
    Guo J, Xiao B, Lou Y, Yan C, Zhan L, Wang D, Zhao W.
    J Gastroenterol Hepatol; 2006 Feb 01; 21(2):443-8. PubMed ID: 16509872
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus in combination with FTY720: analysis of urinary and serum parameters.
    Lopes CT, Pletiskaitz TM, de Franco MF, Cordeiro JA, Bueno V.
    Transplant Proc; 2010 Mar 01; 42(2):582-4. PubMed ID: 20304197
    [Abstract] [Full Text] [Related]

  • 16. [Effect of chemotherapy with cisplatin and rapamycin against Hep-2 cells in vitro].
    Lei WB, Jia T, Su ZZ, Wen WP, Zhu XL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct 01; 28(10):1838-41. PubMed ID: 18971185
    [Abstract] [Full Text] [Related]

  • 17. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
    Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, Ichinokawa K, Itoh T, Shichinohe T, Hirano S, Kondo S.
    Int J Oncol; 2009 May 01; 34(5):1231-40. PubMed ID: 19360336
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
    Böhler T, Schütz M, Budde K, Neumayer HH, Waiser J.
    Int Immunopharmacol; 2007 Jan 01; 7(1):88-95. PubMed ID: 17161821
    [Abstract] [Full Text] [Related]

  • 19. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.
    Neurology; 2008 Oct 14; 71(16):1261-7. PubMed ID: 18852441
    [Abstract] [Full Text] [Related]

  • 20. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC.
    Clin Cancer Res; 2009 Jul 01; 15(13):4322-35. PubMed ID: 19509141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.